| abstract |
The present invention concerns a novel fused bicyclic heteroaryl derivative or the pharmaceutically acceptable salt thereof which has excellent blood-sugar reduction activity, can treat and/or prevent the sugar and the lipid metabolic disease or the peroxysome activation receptor (PPAR)γ intermediate disease. (means for solving the problems) A compound of the following formula (I) [wherein, R1 represents Cl-C6 alkyl group, a C6-C10 aryl group which may be substituted with 1 to 5 groups independently selected from substituents b; R2 represents a C1-C6 alkyl group; R3 represents a C6-C10 aryl group which may be substituted with 1 to 5 groups independently selected from substituents b etc.; Q represents a group of =CH- or a nitrogen atom; substituents a represents a group selected from a halogen atom, a C1-C6 alkyl group, a C1-C6 hydroxyalkyl group, etc.], or the pharmaceutically acceptable salt thereof. |